用于腺干细胞心肌固定术的生物技术。

Bio-technologies for a glandular stem cell cardiomyopexy.

作者信息

Guldner Norbert W, Klapproth Peter, Schwarz Philipp O, Hardel Tim, Rumpf Philipp M, Kajahn Jenny, Margaritoff Petra, Sievers Hans H, Grossherr Martin

机构信息

Cardiac Surgery Division, University Hospital of Schleswig Holstein, Campus Luebeck, Ratzeburger Allee 160, D-23538 Luebeck, Germany.

出版信息

Ann Anat. 2009 Jan;191(1):45-50. doi: 10.1016/j.aanat.2008.08.003. Epub 2008 Sep 27.

DOI:10.1016/j.aanat.2008.08.003

PMID:18950997

Abstract

The glandular stem cell cardiomyopexy should become a treatment option for end-stage heart failure. It combines an expected regenerative potential of transformed adult glandular stem cells into cardiomyocytes within the myocardium or onto the myocardium of the recipient and the potential of a hypercapillarized latissimus dorsi muscle (LDM) wrapped around the heart for stem cell nutrition and girdling.

摘要

腺干细胞心肌固定术应成为终末期心力衰竭的一种治疗选择。它结合了转化后的成体腺干细胞在受体心肌内或心肌上转化为心肌细胞的预期再生潜力，以及包裹在心脏周围的高毛细血管化背阔肌为干细胞提供营养和环绕的潜力。